Hinge Health (NYSE: HNGE) has received a bullish upgrade from Royal Bank of Canada, which raised its target price from $110.00 to $135.00. The bank maintains an "outperform" rating on the stock, suggesting a potential upside of 16.01% from its current price. This move comes amid a wave of positive analyst sentiment, with several other firms also increasing their price targets and reaffirming their bullish outlooks on the digital healthcare company.
The stock has been on a strong upward trajectory, trading at $116.37 on Tuesday, up $0.89 from the previous close. Hinge Health's 52-week range spans from $30.08 to $118.86, reflecting significant growth. The company's market capitalization stands at $9.39 billion, with a price-to-earnings ratio of 91.44, indicating a high valuation.
Hinge Health recently reported impressive third-quarter results, with revenue of $234.97 million, up 52.4% year over year, and earnings per share of $0.71, surpassing analyst estimates. The company also raised its revenue guidance for the fourth quarter and full year, further boosting investor confidence. However, some analysts caution that the stock's high valuation may limit further gains if future results do not meet elevated expectations.
Insider activity has been notable, with CEO Daniel Perez and Chairman Gabriel Mecklenburg selling significant shares of the company's stock in recent months. Despite these sales, institutional investors have been increasing their stakes, suggesting long-term confidence in the company's prospects.